Phosphospecific Antibodies Targeting Tau Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for neurodegenerative tauopathies, such as Alzheimer's Disease, face challenges in specificity and efficacy due to difficulties in targeting intra-neuronal tau aggregates, with existing immunotherapies showing limited effectiveness in reducing tau pathology and cognitive deficits.
Innovation Solution
Development of antibodies that specifically recognize and bind to phosphorylated tau protein epitopes, particularly the phospho-epitope Tau aa 396-401 with a phosphorylated Ser at position 396, with a dissociation constant between 2 nM and 80 nM, capable of modulating levels of soluble and insoluble phosphorylated tau in vivo, and designed as monoclonal, chimeric, or humanized IgG2b, IgG2a, or IgG3 antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immunotherapies are used to target tau aggregates, then therapeutic intervention is provided, but specificity and efficacy are limited due to difficulty in targeting intra-neuronal tau aggregates
Solution Approach 1:
The antibody is engineered to recognize a specific local epitope (phosphorylated serine 396 within amino acid sequence 393-401) on the tau protein rather than attempting to recognize entire tau aggregates. This localized recognition approach enables the antibody to specifically bind to pathological phospho-tau conformers while maintaining ability to penetrate and target intra-neuronal aggregates, thereby improving both specificity and therapeutic effectiveness.
2Measurement precision
If antibodies target phosphorylated tau epitopes with high specificity, then cognitive functions may be improved, but the complexity of antibody design and production increases
Solution Approach 1:
The antibody design focuses on recognizing a specific phosphorylation state (phosphorylated serine 396) rather than the entire tau protein structure. This parameter-based recognition approach simplifies the manufacturing process by enabling the use of peptide-based immunogens during antibody development, while still achieving high specificity for pathological phospho-tau conformers in the final therapeutic product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies effectively detect and modulate tau protein levels, potentially slowing or halting the progression of tauopathies, improving cognitive functions, and alleviating symptoms associated with tau-related diseases by specifically targeting pathological tau conformers.
Implementation Method 1
antibodies that specifically recognize and bind to phosphorylated tau protein epitopes, particularly the phospho-epitope Tau aa 396-401 with a phosphorylated Ser at position 396, with a dissociation constant between 2 nM and 80 nM
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).